Hormone replacement therapy is the single biggest demand story of the week. Wikipedia pageviews for HRT jumped 99% week-over-week, driving an Emerging Demand Index score of 3.34 — roughly 4x the next-highest signal. That kind of step-change in consumer research traffic typically precedes a 2-4 week lift in consult requests at menopause and women's health clinics.

Emerging Demand — What to Watch

  • HRT — EDI 3.34 (Menopause, Women's Health). Mechanism: Wikipedia pageviews +99% WoW. This is a pure consumer-attention signal, not regulatory — meaning it's likely media- or influencer-driven and will convert to booking intent fastest.
  • Anxiety — EDI 0.84 (Psychiatry, Mental Health). Mechanism: 31 new recruiting clinical trials in the last 30 days. This is a pipeline/research signal rather than a search signal — useful for trial-affiliated practices and behavioral health groups tracking sponsor activity.
  • Zepbound — EDI 0.80 (Weight Loss). Mechanism: Wikipedia pageviews +27% WoW. Consumer curiosity around tirzepatide branding continues to compound; this is the third straight week Zepbound has out-paced Mounjaro in pageview growth.
  • Mounjaro — EDI 0.34 (Weight Loss). Mechanism: Wikipedia pageviews +14% WoW. Same GLP-1 tailwind, weaker magnitude — Zepbound is winning the branded-search war for new entrants.
  • Obesity — EDI 0.16 (Bariatrics). Mechanism: 33 new recruiting trials (30d) offsetting a -4% WoW pageview dip. Trial volume is doing the heavy lifting; consumer attention is flat, suggesting the GLP-1 conversation has consolidated around brand names rather than the underlying condition.

Search Intent

Google Trends shows no nationally rising conditions this week, but two notable declines. Joint replacement searches fell 16% on a 4-week average basis (51 → 43), and back pain searches dropped 13% (81 → 71). The joint replacement decline contradicts the typical early-summer pattern and suggests elective orthopedic intent is softening — possibly as consumers defer surgical consults into Q3. No Google signal corroborates the HRT or GLP-1 EDI moves yet, which means the Wikipedia-driven leading indicators have not yet translated into broad query volume. Expect that confirmation in the next 1-2 weeks.

Structural Markets

With no fresh BRFSS state-level deltas this cycle, the structural read is unchanged: menopause-age female prevalence remains concentrated in the Southeast and Mountain West, which is where the HRT pageview surge will likely convert most efficiently. Operators in those regions with women's health lines should weight paid acquisition toward HRT keywords this week given the 99% pageview lift has not yet shown up in CPC inflation.

The Bottom Line

Reallocate ad spend and intake capacity toward HRT and menopause this week — the 99% Wikipedia surge is a clean leading indicator and CPCs haven't caught up yet. Orthopedic groups should pull back on elective-surgery acquisition spend given the 16% drop in joint replacement intent, and GLP-1 clinics should bias creative toward Zepbound branding over Mounjaro.